Cathy Eng, MD (IMAGE)

ECOG-ACRIN Cancer Research Group

Cathy Eng, MD

Caption

Cathy Eng, MD (Vanderbilt-Ingram Cancer Center and ECOG-ACRIN Cancer Research Group), who is leading a new phase 3 trial for patients with metastatic anal cancer, says that the trial "is exploring whether the addition of immunotherapy to standard therapy will extend progression-free survival."

Credit

Vanderbilt-Ingram Cancer Center

Usage Restrictions

None

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.